Cellectar Biosciences, Inc. filed an 8-K on June 26, 2025, reporting plans to initiate Phase 1b clinical studies for CLR 125, which has shown promise in treating triple negative breast cancer with minimal toxicity in animal models, while CLR 225 also demonstrated effective tumor reduction in pancreatic cancer models. The company aims to fund these studies through a proposed securities offering.